Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.
暂无分享,去创建一个
[1] M. Kris,et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Crowley,et al. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Edward S. Kim,et al. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] N. Hanna,et al. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Thomas J Lynch,et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. , 2004, Lung cancer.
[6] F. Cappuzzo,et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[8] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[9] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[10] A. Tolcher,et al. Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule , 2004, Clinical Cancer Research.
[11] T. Kijima,et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. , 2004, Clinical lung cancer.
[12] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[13] R. Ramlau,et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Argiris,et al. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. , 2004, Lung cancer.
[15] G. Giaccone,et al. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Manuel Hidalgo,et al. An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors , 2004, Cancer Research.
[17] U. Gatzemeier,et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) , 2004 .
[18] G. Giaccone,et al. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. , 2003, Drugs of today.
[19] M. Sliwkowski,et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.
[20] J. Rigas,et al. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] L. Ellis,et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. , 2004, Molecular cancer therapeutics.
[22] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[23] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] T. Crombet,et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] F. Cappuzzo,et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Kris,et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer , 2003, British Journal of Cancer.
[28] A. Rossi,et al. Gefitinib as salvage therapy in pretreated patients with advanced non-small cell lung cancer. Data from a compassionate use program. , 2004, Anticancer Research.
[29] F. Cappuzzo,et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. , 2004, Journal of the National Cancer Institute.
[30] William Pao,et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J. Baselga,et al. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] M. Alloisio,et al. Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] G. Chang,et al. Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status , 2004, Investigational New Drugs.
[34] Neil A. Reynolds,et al. Cetuximab , 2004, Drugs.
[35] Roy S Herbst,et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Xin Li,et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] R. Pazdur,et al. United States Food and Drug Administration Drug Approval Summary , 2004, Clinical Cancer Research.
[38] F. Gao,et al. Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience. , 2004, Lung cancer.
[39] G. Peters,et al. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] K. Kiura,et al. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. , 2004, Lung cancer.
[41] G. Giaccone,et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] L. Desantis,et al. Travoprost: a potent ocular hypotensive agent. , 2003, Drugs of today.
[43] R. Herbst,et al. TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] E. Cook,et al. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[45] J. Minna,et al. Molecular genetics of lung cancer. , 2003, Seminars in oncology.
[46] M. Kris,et al. Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] L. Crinò,et al. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC) , 2004, British Journal of Cancer.
[48] J. Mestan,et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. , 2004, Cancer research.
[49] A. Bezjak,et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial , 2004 .